Bioceres | Bioceres S.A. Announces Filing of Registration Statement for Proposed Initial Public Offering of American Depositary Shares

Bioceres S.A. Announces Filing of Registration Statement for Proposed Initial Public Offering of American Depositary Shares

8 January, 2018

Rosario, Argentina–Bioceres S.A. (“Bioceres”), a fully-integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants and micro-beaded fertilizers, announced today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) for a proposed initial public offering in the United States of American Depositary Shares (“ADSs”) representing its ordinary shares. The number of ADSs to be offered and the price range for the proposed offering have not yet been determined. Bioceres has applied to list its ADSs on the New York Stock Exchange under the ticker symbol “BIOX”.

Jefferies is acting as sole global coordinator and Jefferies and Piper Jaffray are acting as joint book-running managers for the offering. Santander is also acting as a joint book-running manager. Mirabaud Securities is acting as co-manager.

The securities referred to in this release are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by email at [email protected]; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-7473924 or by email at [email protected]

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time when the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Bioceres has also filed a petition for the authorization of the public offering of its ordinary shares in Argentina before the Argentine Securities and Exchange Commission (Comisión Nacional de Valores) but such authorization has not yet been granted.